Limitations to the use of carboplatin-based therapy in advanced ovarian cancer
Most patients with recurrent ovarian cancer (ROC) undergo a series of remissions and recurrences, therefore the additive or cumulative toxicity of chemotherapy must be factored into their treatment plan. There are challenges in defining tailored therapeutic approaches, including optimal timing and d...
Main Author: | Christina Fotopoulou |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2014-12-01
|
Series: | EJC Supplements |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1359634915700054 |
Similar Items
-
Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin
by: Shinichi Tate, et al.
Published: (2021-02-01) -
Inhibition of XIAP increases carboplatin sensitivity in ovarian cancer
by: Zhang Y, et al.
Published: (2018-12-01) -
Select Per‐ and Polyfluoroalkyl Substances (PFAS) Induce Resistance to Carboplatin in Ovarian Cancer Cell Lines
by: Fenton, S.E, et al.
Published: (2022) -
Intraperitoneal, Continuous Carboplatin Delivery for the Treatment of Ovarian Cancer
by: Zhidkov, Nickholas
Published: (2012) -
Intraperitoneal, Continuous Carboplatin Delivery for the Treatment of Ovarian Cancer
by: Zhidkov, Nickholas
Published: (2012)